Cediranib (CAS 288383-20-0) Suppliers and Product Information

Cediranib is a potent inhibitor of VEGFR tyrosine kinases, including VEGFR1, VEGFR2, and VEGFR3. It also inhibits other receptor and non-receptor tyrosine kinases in the platelet-derived growth factor, fibroblast growth factor, and endothelial growth factor receptor families. Cediranib has shown potential in blocking angiogenesis and inhibiting tumor growth in various cancer studies.

Frequently Asked Questions about Cediranib

Q: What is the primary mechanism of action for Cediranib?

A: Cediranib is a highly potent inhibitor of VEGFR tyrosine kinases, particularly VEGFR2 (KDR), with an IC50 of less than 1 nM. It blocks VEGF-induced angiogenesis, neovascularization, and tumor cell growth.

Q: What types of cancer has Cediranib been studied for?

A: Cediranib has been investigated for various cancers, including non-small cell lung cancer (NSCLC), metastatic renal cell carcinoma (mRCC), and cervical cancer. Clinical trials have explored its use both as a monotherapy and in combination with other treatments.

Q: Are there any notable side effects associated with Cediranib?

A: Clinical trials have reported side effects such as diarrhea, dehydration, hand-foot syndrome, hypertension, and neutropenia. Some of these adverse effects appear to be dose-related, and dose adjustments have been explored to improve drug tolerance.

Q: How is Cediranib typically administered?

A: Cediranib is an oral anticancer drug. In clinical trials, doses have ranged from 20 mg to 30 mg, with recent studies focusing on lower doses to improve tolerability.